Ersodetug (9 mg/kg) + SOC
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tumor-associated Hyperinsulinism (Tumor HI)
Conditions
Tumor-associated Hyperinsulinism (Tumor HI)
Trial Timeline
— → —
NCT ID
NCT07262970About Ersodetug (9 mg/kg) + SOC
Ersodetug (9 mg/kg) + SOC is a pre-clinical stage product being developed by Rezolute for Tumor-associated Hyperinsulinism (Tumor HI). The current trial status is active. This product is registered under clinical trial identifier NCT07262970. Target conditions include Tumor-associated Hyperinsulinism (Tumor HI).
Hype Score Breakdown
Clinical
3
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07262970 | Pre-clinical | Active |